Treatment of disseminated paraganglioma with gemcitabine and docetaxel

Pediatric Blood and Cancer

Volumn 53, Issue 4, 2009, Pages 663-665

  Mora, Jaume ^a,b   Cruz, Ofelia ^a   Parareda, Andreu ^a   Sola, Teresa ^a   De Torres, Carmen ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Docetaxel; Gemcitabine; Metastatic paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; C REACTIVE PROTEIN; CHROMOGRANIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HOMOVANILLIC ACID; IBUPROFEN; IFOSFAMIDE; ONDANSETRON; PROPRANOLOL; PROTEIN S 100; RANITIDINE; SYNAPTOPHYSIN; VANILMANDELIC ACID; VINCRISTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ABDOMINAL MASS; ADOLESCENT; ARTERIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISSEMINATED CANCER; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEVER; HAIR LOSS; HUMAN; HYPOCHONDRIASIS; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TEST; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PAIN; PARAGANGLIOMA; PERIPHERAL EDEMA; PORTAL HYPERTENSION; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; SKIN TOXICITY; TACHYCARDIA; TREATMENT RESPONSE; TUMOR BIOPSY; UMBILICUS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; MALE; PARAGANGLIOMA; TAXOIDS;

EID: 69849093934     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22006     Document Type: Article

References (14)

1. Fitzgerald PA. Pheochromocytoma and paraganglioma. In: Clark OH, Duh QY, Perrier ND, Jahan TM, editors. Endocrine tumors. Hamilton, Ontario: Becker, Inc., American Cancer Society; 2003. pp. 100-122.
2. Kruijtzer CM, Beijnen JH, Swart M, et al. Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature. Cancer Chemother Pharmacol 2000;45:428-431.
3. Patel S, Winchester D, Benjamin R. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 1995;76:1476-1480.
4. Massey V, Wallner K. Treatment of metastatic chemodectoma. Cancer 1992;69:790-792.
5. Mora J, Cascón A, Robledo M, et al. Pediatric paraganglioma: An early manifestation of an adult disease secondary to germline mutations. Pediatr Blood Cancer 2006;47:785-789. (Pubitemid 44476754)
6. Pipas JM, Krywicki RF. Treatment of progressive metastatic glomus jugulare tumor (paraganglioma) with gemcitabine. Neuro Oncol 2000;2:190-191.
7. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res 1992;52:533-539.
8. Anderson PM, Wiseman GA, Erlandson L, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005;11:6895-6900. (Pubitemid 41428746)
9. Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 2003;88:1963-1970. (Pubitemid 36829675)
10. Bissery MC, Guénard D, Guéritte-Voegelein F, et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51:4845-4852.
11. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824-2831. (Pubitemid 34651511)
12. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas. J Clin Oncol 2007;25:2755-2763. (Pubitemid 47123184)
13. Hahn NM, Reckova M, Cheng L, et al. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 2009;27:460-463.
14. Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009;94:5-9.